Devita, Hellman, and Rosenberg's Cancer

LWBK1006-27 LWW-Govindan-Review December 12, 2011 19:32

376 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 27.5. A healthy 42-year-old woman was recently found to have a 2.4-mm

Breslow thickness nonulcerated primary cutaneous superficial spreading

melanoma. The pigmented lesion was excised from her left lower extrem-

ity by her local dermatologist. The physician calls you for advice regarding

further evaluation. Your recommendation is which of the following:

A. Referral to a medical oncologist for a clinical trial

B. Body positron emission tomography/computed tomography (PET-

CT) scan for initial staging

C. Referral to a surgeon for wide local excision and sentinel lymph node

mapping

D. Annual follow-up for skin checks

Question 27.6. A 56-year-old man was recently diagnosed with a stage IIa primary cuta-

neous melanoma (T2b N0 Mx). What is the most appropriate recom-

mendation for clinical follow-up?

A. Annual visit with a dermatologist

B. Office visits with a dermatologist every 3 months for 3 years, every

6 months for 2 years, and then annually for life

C. Office visits with a dermatologist every 3 months for 3 years, every

6 months for 2 years, and then annually for life plus body PET-CT

imaging every 6 months for life

D. Office visits with a dermatologist every 3 months for life

Question 27.7. Indications for radiation therapy in the treatment of melanoma include

which of the following:

A. Symptomatic brain metastases

B. Choroidal melanoma

C. Symptomatic bone metastases

D. All of the above

Question 27.8. The MOST common first metastatic site for ocular melanoma is:

A. Brain

B. Lung

C. Liver

D. Skin

Question 27.9. What stage best defines a patient with a 3 mm ulcerated tumor, 4 regional

lymph nodes involved and no detectable distant metastases?

A. T3bN2b (IIIA)

B. T3aN2b (IIIB)

C. T3bN3 (IIIB)

D. T3bN3 (IIIC)